Lipoprotein based drug delivery: Potential for pediatric cancer applications

Table 2 Drug delivery formulations currently undergoing clinical trials for pediatric cancers

FDA approvedFormulations	Drug	Phase of pediatricclinical trial	Type of cancer	Ref.
Abraxane	Paclitaxel	Preclinical	Rhabdomyosarcoma Osteosarcoma Neuroblastoma	[30]
Nab paclitaxel	Paclitaxel	Phase I and II	Rhabdomyosarcoma, neuroblastoma	[41]
Doxil	Doxorubicin	Phase I and II	Refractory or recurrent Rhabdomyosarcoma, Neuroblastoma, Pontine glioma	[31]
DaunoXome	Daunorubicin	Phase III	AIDS related Kaposi Sarcoma, pediatric in acute myloid leukemia refractory/relapsed	[32]
L-Annamycin	L-Annamycin	Phase I	Acute lymphocytic and acute myloid Leukemia	[42]
Depocyte (liposomalformulation)	Cytarabine	Phase I	Acute lymphocytic leukemia	[43]
			Recurrent brain tumor	[44]
Marquibo	Vincristine sulfate	Phase I	Sarcoma	[45]
		Phase II	Neuroblastoma
CPX 351	Cytarabine and daunorubicin	Phase I	Relapsed leukemia or lymphoma	[46]

FDA: United States Food and Drug Administration.